Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery

Journal of the National Medical Association

Volumn 90, Issue 11, 1998, Pages 677-680

  Saunders, Michael E ^a   Grant, Richard E ^a  

^a HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

Deep vein thrombosis; Enoxaparin; Hip replacement; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; WARFARIN;

AFRICAN AMERICAN; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HIP ARTHROPLASTY; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; THROMBOPHLEBITIS; UNITED STATES;

AFRICAN AMERICANS; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; COST-BENEFIT ANALYSIS; DISTRICT OF COLUMBIA; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOPHLEBITIS; WARFARIN;

EID: 0032215607     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hull R, Raskob G, Pineo G, Rosenbloom D, Williams E, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1371-1376.
2. Leyvaz P, Bachmann F, Bohnet J, Breyer HG, Estoppey D, Hass S, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular heparrinoid lomoparan and heparin dihydroergotamine. Br J Surg. 1992;79:911-914.
3. Lindhout T, Hemker HC. Anticoagulant mechanism of action of low molecular weight heparins. In: Doutremepuich C, ed. Low Molecular Weight Heparins in Clinical Practice. New York, NY: Marcel Dekker Inc; 1992.
4. Ohar JA: Anticoagulant therapy for the 90's. Anticoagulant Therapy. 1994;16:41-55.
5. Hirsh J, Levin MN. Low molecular weight heparin. Blood. 1992;79:1-17.
6. Bergqvist D, Matzseh T. Cost/benefit aspects on thromboprophylaxis. Haemostasis. 1993;3(supp 1):15-19.
7. Hull R, Raskob G, Pineo G, Green D, Trowbridge AA, Elliott CG. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-982.
8. Nurmohamed MT, Sorendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152-156.
9. Turpie AGG, Levine M, Hirsh J, Carter CJ, Jay RM, Powers PJ. A randomized trial of low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315:925-929.
10. Anderson DR, O'Brien BJ, Levine M, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993;119:1105-1112.
11. Janvier G, Winnock S. Treatment of deep vein thrombosis with low molecular weight heparins. In: Doutremepuich C, ed. New York, NY: Marcel Dekker Inc; 1992:109-124.
12. Barrowcliffe TW. Standardization of assays of low molecular weight heparin. In: Doutremepuich C, ed. New York, NY: Marcel Dekker Inc; 1992:155-169.
13. Hull RD, Pineo GF. Therapeutic use of low molecular-weight heparins. Haemostasis. 1993;23(supp 1):2-9.